Public Health Update: Youth E-Cigarette Use and EVALI Outbreak
Once you're logged in, please select the "REGISTER" tab to process your payment and complete your registration.
Once you register for the course, you will have 30 days (approximately 1 month) from the date of enrollment to complete the course. The exact date that your access expires will be indicated within the Course Summary box on this webpage.
As teen use of e-cigarettes continues to rise and the vaping-related respiratory illness health crisis grows across Iowa and our nation, the Iowa Tobacco Use Prevention and Control Commission believes it is time for our state legislators to take action.
As of October 15, 2019, the Centers for Disease Control and Prevention (CDC) has reported 1,479 lung injury cases over the last few months. There have been 34 confirmed deaths in 24 states. Most patients have reported the use of vaping and e-cigarette products containing THC. However, products and devices that do not contain THC have also been reported. Case numbers will likely continue to increase as the CDC and FDA investigation into the cause of lung injury continues.
Here in Iowa, there have been 41 reported lung injury cases. There have been no confirmed deaths; however, several of the patients have serious lung damage that may continue to make them vulnerable for the remainder of their lives.
According to the New England Journal of Medicine, national rates of teen vaping more than doubled between 2017 and 2019, with over 25% of 12th graders reporting vaping in 2019. In Iowa, e-cigarette use more than doubled between 2016 and 2018, with 22.4% of 11th graders reporting vaping in 2018. With nearly 400 vape flavors, like cotton candy and bubblegum, it is clear these products are designed to appeal to teens and go unnoticed by adults.
Source: George Belitsos, Chair of the Iowa Tobacco Use Prevention and Control Commission via The Des Moines Register
Below is a video on e-cigarettes and the emerging threat faced by rising youth use rates from Tobacco Control Network (TCN), Luci Longoria, and Dr. Brian King, CDC’s Office on Smoking and Health Deputy Director for Research Translation.
- Discuss the youth vaping epidemic.
- Describe epidemiology of the EVALI outbreak.
- Describe clinical management guidelines.
- Review a sample case of EVALI.
- Describe tobacco and vaping cessation tools.
Photo: Lauren Bishop, CDC/Von Roebuck. Retrieved from the CDC's Public Health Image Library. Public Domain.
Date of original release: March 6, 2020
Most recent review/update: March 6, 2020
Termination date: March 5, 2023
Caitlin Pedati, MD, MPH, FAAP
State Epidemiologist and Medical Director, Iowa Department of Public Health
Nick Kalas, MPH
Epidemiologist, Iowa Department of Public Health
The speakers have no financial conflicts with commercial interest companies to disclose relevant to the content of this educational activity.
Continuing Education Credit
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 0.75 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Other Healthcare Professionals: This enduring materials activity is designated for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.
No commercial interest company provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 0.75 AMA PRA Category 1 Credits™
- 0.75 AOA Category 2B
- 0.75 CE Contact Hour(s)